Albany Molecular Research (AMRI) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
AMRI Announces First Quarter 2017 Results
May 9, 2017 7:30 AM EDTALBANY, N.Y., May 9, 2017 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2017 and provided an update to its outlook for 2017.
Highlights:
First quarter total revenue of $163.8 million, up 55% from 2016 First quarter basic and diluted EPS $(0.25); non-GAAP diluted EPS of $0.13 First quarter net loss of $(10.7) million; non-GAAP net income of $5.7 million First quarter adjusted EBITDA of $24.0 million, up 83% from 2016 Company confirms 2017 financial guidanceNon-GAAP net income, non-GAAP diluted EPS... More
